|View printer-friendly version|
For more information on the CyberKnife and TomoTherapy Systems visit www.accuray.com.
The stereotactic radiosurgery center (SRC) 'Sigulda,' located in Sigulda, is the first center to offer CyberKnife M6 System treatments in the Baltic region. SRC 'Sigulda' plans to use the system to treat both oncological and non-oncological diseases.
The CyberKnife M6 Series delivers radiosurgery and stereotactic body radiation therapy (SBRT), enabling precise, high-quality dose distributions to be confidently administered to the patient with extreme accuracy over a minimum number of treatments, reducing side effects and preserving patients' quality of life. Using its unique robotic range of motion and continuous image guidance, the system follows the target throughout the treatment process, delivering individualized treatment with sub-millimeter precision.
Based on a CT scanner platform, the TomoTherapy® System provides continuous delivery of radiation from 360 degrees around the patient, or delivery from clinician-specified beam angles. These unique features, combined with daily 3D image guidance, enable physicians to deliver highly accurate, individualized dose distributions which precisely conform to the shape of the patient's tumor while minimizing dose to normal, healthy tissue, resulting in fewer side effects for patients.
"The recent installations of
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to market adoption of the company's products, clinical applications, clinical results, patient outcomes and
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. The company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not put undue reliance on any forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/accuray-announces-first-radiation-therapy-systems-installed-in-qatar-latvia-and-bulgaria-300201645.html
Beth Kaplan, Accuray, +1 (408) 789-4426, email@example.com; or Kirsten Fallon, MSLGROUP in Boston, +1 (781) 684-0770, Kirsten.Fallon@MSLGROUP.com
© 2007 - 2016 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi-Art, and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries.
Important Safety Information: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death.
Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.